Selecta Biosciences to Participate at the 20th Annual Needham Healthcare Conference

Rhea-AI Summary

Selecta Biosciences, Inc. (NASDAQ: SELB) announced that CEO Carsten Brunn, Ph.D., will participate in the virtual 20th Annual Needham Healthcare Conference from April 12-15, 2021. The fireside chat is scheduled for April 13 at 3:00 p.m. ET, with a webcast available for viewing.

Additionally, Selecta is enhancing its ImmTOR™ platform to develop therapies that reduce unwanted immune responses and is entering clinical trials for gene therapies. Recent licensing of SEL-212 for chronic refractory gout underscores its innovative approach.

WATERTOWN, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate in a fireside chat and one-on-one investor meetings at the virtual 20^th Annual Needham Healthcare Conference to be held April 12-15, 2021.

Details on the presentation can be found below.

Date: Tuesday, April 13
Fireside chat time: 3:00 p.m. ET
Webcast: Click Here

An archived webcast will also be available in the Investors & Media section of the company’s website at www.selectabio.com.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. The company’s first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in partnership with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi. For more information, please visit www.selectabio.com.

For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com

For Media:
Meredith Sosulski, Ph.D.
LifeSci Communications, LLC
+1-929-469-3851
msosulski@lifescicomms.com

FAQ

What is the date of Selecta Biosciences' fireside chat at the Needham Healthcare Conference?

The fireside chat is scheduled for April 13, 2021.

What time will the fireside chat with Selecta Biosciences' CEO take place?

The chat will take place at 3:00 p.m. ET.

How can I access the webcast of Selecta Biosciences' fireside chat?

The webcast can be accessed through the company's website, with a link provided in the press release.

What is the focus of Selecta Biosciences' ImmTOR™ platform?

The ImmTOR™ platform focuses on developing therapies that mitigate unwanted immune responses.

What clinical trials is Selecta Biosciences entering in 2021?

Selecta is expected to enter clinical trials for its program targeting methylmalonic acidemia in early 2021.